Trial reportBMC medicine2025
Efficacy of standard care versus acoustic therapy on acute tinnitus in idiopathic sudden sensorineural hearing loss: a randomized controlled trial.
Trial report in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Efficacy of sound therapy on tinnitus in idiopathic sudden sensorineural hearing loss: a systematic review and meta-analysis protocol.BMJ open · 2026Article
- Vicious cycle: the bidirectional relationship and pathophysiological mechanisms of tinnitus and sleep disturbance.Frontiers in neurology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
Abstract
backgroundIdiopathic sudden sensorineural hearing loss (ISSHL) frequently occurs with acute tinnitus, causing significant quality-of-life disturbances. Acoustic therapy (AT) is commonly used, but its efficacy remains uncertain. This study aimed to compare the short-term and long-term efficacy of standard care versus AT in reducing tinnitus-related disturbances in ISSHL patients.
methodsThis study was designed as a two-stage approach. In stage I, a multi-center, multi-arm randomized controlled trial was conducted from May 1, 2019, to April 12, 2024, across 19 hospitals in Sichuan, China, involving 213 ISSHL patients with tinnitus. In stage II, participants were given the option to either continue personalized AT treatment at home or explore alternative therapeutic options, with their decisions and subsequent outcomes objectively monitored and recorded over a period of 6 months. Participants were randomly assigned to four groups for a short-term (10 days) inpatient intervention: Group A (international standard care: systemic steroid), Group B (Chinese standard care: systemic steroid plus intravenous batroxobin), Group C (international standard care with daily AT), and Group D (Chinese standard care with daily AT). After discharge, participants underwent a 170-day follow-up with optional long-term domestic AT. The primary outcome was short-term tinnitus remission (TR). Secondary outcomes included short-term changes in Tinnitus Handicap Inventory (THI), Tinnitus Questionnaire (TQ), customized visual analog scale (VAS) for hearing loss (HL-VAS) and tinnitus (T-VAS), Beck Anxiety Inventory (BAI), Beck Depression Inventory (BDI), 36-Item Health Survey Short Forms (SF-36), and the Pittsburgh Sleep Quality Index (PSQI) scores, and long-term changes including TR and HL-VAS and T-VAS.
resultsAmong 213 enrolled participants, short-term analyses showed no statistically significant differences in TR or other outcomes (THI, TQ, BAI, BDI, SF-36, PSQI) among groups. Long-term analyses revealed higher TR in severe ISSHL patients who received long-term domestic AT (45.5% vs. 20.0%, P = 0.034), with no significant differences in other outcomes. Severe adverse events and deaths were not reported.
conclusionsAT may not provide immediate relief but shows potential for sustained TR in severe ISSHL. Future studies should optimize its timing, duration, and integration into treatment strategies.
trial registrationThis trial was registered at the Chinese Clinical Trial Registry (ChiCTR1900021725).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.